MicroRNA-27a-3p Reverses Adriamycin Resistance by Targeting BTG2 and Activating PI3K/Akt Pathway in Breast Cancer Cells.
BTG2
adriamycin
breast cancer
chemoresistance
miR-27a-3p
Journal
OncoTargets and therapy
ISSN: 1178-6930
Titre abrégé: Onco Targets Ther
Pays: New Zealand
ID NLM: 101514322
Informations de publication
Date de publication:
2020
2020
Historique:
received:
30
03
2020
accepted:
11
06
2020
entrez:
9
8
2020
pubmed:
9
8
2020
medline:
9
8
2020
Statut:
epublish
Résumé
This study aimed to explore the regulative mechanisms of miR-27a-3p in chemo-resistance of breast cancer cells. qRT-PCR was employed to determine miR-27a-3p expression in two breast cancer cell lines, MCF-7 and MCF-7/adriamycin-resistant cell line (MCF-7/ADR). The two cell lines were treated with miR-27a-3p mimics or inhibitors or corresponding negative control (NC), respectively. The changes were investigated by qRT-PCR, CCK-8 assay, Western blot (WB), colony formation assay, and flow cytometry assay. Moreover, luciferase reporter assay was analyzed to verify the downstream target gene of miR-27a-3p. Further investigation in the correlation between miR-27a-3p and BTG2 was launched by WB, flow cytometry assay, and CCK-8 assay. The expression of Akt and p-Akt was detected by WB. Significantly higher miR-27a-3p expression was confirmed in MCF-7/ADR as compared with sensitive cell line MCF-7 ( miR-27a-3p might be associated with resistance of breast cancer cells to adriamycin treatments, modulating cell proliferation and apoptosis by targeting BTG2 and promoting the PI3K/Akt pathway in breast cancer cells. miR-27a-3p/BTG2 axis might be a potential therapeutic target for clinical BC resistance.
Identifiants
pubmed: 32764979
doi: 10.2147/OTT.S256153
pii: 256153
pmc: PMC7368588
doi:
Types de publication
Journal Article
Langues
eng
Pagination
6873-6884Informations de copyright
© 2020 Zhu et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Oncogene. 2004 Oct 28;23(50):8310-9
pubmed: 15378000
Cell Physiol Biochem. 2017;42(4):1431-1446
pubmed: 28715819
Oncologist. 2003;8 Suppl 2:3-9
pubmed: 13679590
Oncogene. 2014 May 15;33(20):2629-38
pubmed: 23752185
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
Mol Clin Oncol. 2019 Jul;11(1):15-23
pubmed: 31289672
J Exp Clin Cancer Res. 2011 May 13;30:55
pubmed: 21569481
J Cell Physiol. 2010 Jan;222(1):66-72
pubmed: 19746446
Oncotarget. 2017 Feb 28;8(9):15507-15519
pubmed: 28099945
Cancer Lett. 2017 Oct 28;407:113-122
pubmed: 28412239
Cancer Biomark. 2019;24(1):31-42
pubmed: 30614794
Tumour Biol. 2016 May;37(5):6837-45
pubmed: 26662313
Biochem Biophys Res Commun. 2019 Jul 23;515(2):345-351
pubmed: 31153637
Biochem Biophys Res Commun. 2010 Feb 12;392(3):323-8
pubmed: 20060380
Cancer Epidemiol Biomarkers Prev. 2018 Jul;27(7):746-754
pubmed: 29739748
Cancer Med. 2018 Jan;7(1):184-195
pubmed: 29239139
Lancet. 2015 Feb 26;385 Suppl 1:S37
pubmed: 26312859
Mol Cancer. 2014 Aug 16;13:193
pubmed: 25128483
Cancer Biol Ther. 2016 Apr 2;17(4):400-6
pubmed: 26793992
Cell Mol Life Sci. 2019 Feb;76(3):441-451
pubmed: 30374521
J Natl Compr Canc Netw. 2018 Mar;16(3):310-320
pubmed: 29523670
Cell Commun Signal. 2013 Sep 18;11:69
pubmed: 24047462
Tumour Biol. 2012 Aug;33(4):1223-30
pubmed: 22392501
Oncol Lett. 2019 Sep;18(3):2825-2834
pubmed: 31452761
Cell Signal. 2013 Dec;25(12):2693-701
pubmed: 24018051
Tumour Biol. 2013 Jun;34(3):1605-13
pubmed: 23420441
Breast. 2019 Feb;43:31-38
pubmed: 30415143
BMC Cancer. 2010 Jun 16;10:296
pubmed: 20553615
Cell Physiol Biochem. 2018;45(4):1410-1422
pubmed: 29462818
Med Sci Monit. 2015 May 06;21:1297-303
pubmed: 25943633
Biosci Rep. 2019 May 21;39(5):
pubmed: 30902884
Oncol Rep. 2010 Nov;24(5):1121-31
pubmed: 20878101
Mol Carcinog. 2017 Aug;56(8):1992-1998
pubmed: 28370334
Int J Clin Exp Pathol. 2015 Oct 01;8(10):12410-8
pubmed: 26722427
Drug Resist Updat. 2016 Nov;29:90-106
pubmed: 27912846
J Cell Mol Med. 2011 Oct;15(10):2164-75
pubmed: 21070600
Gynecol Oncol. 2010 Oct;119(1):125-30
pubmed: 20624637
Oncogene. 2014 Oct 30;33(44):5173-82
pubmed: 24166498
Biosci Rep. 2019 Jun 4;39(6):
pubmed: 31072914